ArticleEuropean journal of nuclear medicine and molecular imaging2019
Early lesion detection with
Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Effect ofFrontiers in medicine · 2024Pooled it
- Detection of Biochemically Recurrent Prostate Cancer with [Tomography (Ann Arbor, Mich.) · 2023Pooled it
- Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.European radiology · 2022Pooled it
- Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- Trial
- Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021Trial
- Pelvic lymph-node staging withEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.BMC cancer · 2020Trial
- Observational Management for Patients with Biochemical Recurrence Following Radical Prostatectomy, in the Absence of Detectable Disease on Restaging PSMA PET/CT Imaging.Diagnostics (Basel, Switzerland) · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Impact of Uptake Period onCancers · 2025Article
- How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study.Diagnostics (Basel, Switzerland) · 2025Article
- PSMA PET/CT imaging and its application to prostate cancer treatment.Japanese journal of radiology · 2025Review
- [Salvage lymphadenectomy for recurrent prostate cancer].Urologie (Heidelberg, Germany) · 2024Review
- PSMA imaging as a non-invasive tool to monitor inducible gene expression in vivo.EJNMMI research · 2024Article
- Current status of PSMA-targeted imaging and therapy.Frontiers in oncology · 2023Review
- Changes in Management AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (
methodsA total of 248 consecutive patients were evaluated and underwent scanning with
resultsIn 214 out of 248 PET/CT scans (86.3%), at least one lesion suggestive of cancer recurrence was detected ('positive scan'). Scan positivity increased with higher PSA values: 17/29 scans (59%) with PSA values <0.5 ng/ml; 20/29 (69%) with PSA 0.5 to <1.0 ng/ml; 35/41 (85%) with PSA 1.0 to <2.0 ng/ml; 69/73 (95%) with PSA 2.0 to <5.0 ng/ml; and 73/76 (96%) with PSA ≥5.0 ng/ml. Interestingly, suspicious lesions outside the prostatic fossa were detected in 39-50% of patients with PSA <1.0 ng/ml after radical prostatectomy (i.e. candidates for salvage radiotherapy).
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.